Samanta Kisele
Zurich, ZH 8032, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Corrigendum to "EPICYCLE: A confirmatory preclinical study of the anti-rhabdomyosarcoma efficacy of BET bromodomain and cyclin-dependent kinase 9 inhibitors" [Biomed. Pharmacother. 192 (2025), 118704].
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: February 14, 2026
EPICYCLE: A confirmatory preclinical study of the anti-rhabdomyosarcoma efficacy of BET bromodomain and cyclin-dependent kinase 9 inhibitors.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: September 07, 2025
IAP dependency of T-cell prolymphocytic leukemia identified by high-throughput drug screening.
Journal: Blood
Published: October 10, 2024
Patient-derived tumoroids from CIC::DUX4 rearranged sarcoma identify MCL1 as a therapeutic target.
Journal: Nature communications
Published: September 05, 2024
Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer.
Journal: Molecular cancer therapeutics
Published: May 23, 2023
Single-cell profiling of alveolar rhabdomyosarcoma reveals RAS pathway inhibitors as cell-fate hijackers with therapeutic relevance.
Journal: Science advances
Published: February 08, 2023
Showing 1-9 of 9
Last Updated: 09/26/2026